BioPharma Resources

Drug Trial Radar · NCT07208773

A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors

A Multi-center, Open-label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Preliminary Efficacy of YL201 in Combination With Ivonescimab in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jun 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

260

Planned (sponsor's estimate)

Start

Oct 29, 2025

Primary completion

Jan 2027

Study completion Dec 2027

Sponsor

Sponsor type
Industry
Collaborators
Akesobio
First posted
Oct 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was designed to evaluate the efficacy and safety of YL201 in combination with Ivonescimab (AK112) in subjects with solid tumor.

Conditions

  • Advanced Solid Tumors
  • Non Small Cell Lung Cancer
  • Small Cell Lung Cancer

Interventions

  • YL201Drug

    YL201 will be administered as IV infusion

  • IvonescimabDrug

    Ivonescimab will be administered as IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of adverse events (AEs)Time frame: Approximately within 36 months
  2. Maximum tolerate dose(MTD)Time frame: Approximately within 36 months
  3. Recommended Dose for ExpansionTime frame: Approximately within 36 months
  4. Objective Response Rate (ORR)Time frame: Approximately within 36 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.